Notably, encouraging clinical data from the IMpower150 study demonstrated the efficacy of atezolizumab plus bevacizumab plus carboplatin/paclitaxel doublet chemotherapy (ABCP) in an all‐comer chemotherapy‐naïve patient population with metastatic non‐squamous NSCLC, including those who had previously failed EGFR‐TKIs [14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.